公开(公告)号：US20160311811A1

公开(公告)日：2016-10-27

申请号：US15137161

申请日：2016-04-25

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masato YOSHIDA ,  Kazuaki TAKAMI ,  Yusuke TOMINARI ,  Zenyu SHIOKAWA ,  Akito SHIBUYA ,  Yusuke SASAKI ,  Tony GIBSON ,  Terufumi TAKAGI

IPC: C07D413/14 ,  C07D401/14 ,  C07D403/14 ,  C07D403/04 ,  C07D495/04 ,  C07D487/04 ,  C07D487/10 ,  C07D491/107 ,  C07D409/14 ,  C07D471/10 ,  C07D417/14 ,  C07D471/04

CPC classification number: C07D413/14 ,  A61K9/06 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/4858 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10 ,  C07D491/107 ,  C07D495/04

Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Abstract translation: 其中每个符号如说明书中所定义，或其盐。

公开(公告)号：US20150133451A1

公开(公告)日：2015-05-14

申请号：US14533326

申请日：2014-11-05

Applicant: Takeda Pharmaceutical Company Limited

Inventor： Masato Yoshida ,  Kazuaki TAKAMI ,  Yusuke TOMINARI ,  Zenyu SHIOKAWA ,  Akito SHIBUYA ,  Yusuke SASAKI ,  Tony GIBSON ,  Terufumi TAKAGI

IPC: C07D413/14 ,  C07D401/14 ,  C07D405/14 ,  C07D417/14

CPC classification number: C07D413/14 ,  A61K9/06 ,  A61K9/2018 ,  A61K9/2054 ,  A61K9/4858 ,  C07D401/04 ,  C07D401/14 ,  C07D403/04 ,  C07D403/14 ,  C07D405/14 ,  C07D409/14 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/04 ,  C07D487/10 ,  C07D491/107 ,  C07D495/04

Abstract: The present invention provides a heterocyclic compound having an IRAK-4 inhibitory action, which is useful for the prophylaxis or treatment of inflammatory disease, autoimmune disease, osteoarticular degenerative disease, neoplastic disease and the like, and a medicament containing thereof. The present invention relates to a compound represented by the formula (I): wherein each symbol is as defined in the specification, or a salt thereof.

Abstract translation: 本发明提供具有IRAK-4抑制作用的杂环化合物，其可用于预防或治疗炎性疾病，自身免疫性疾病，骨关节炎性退行性疾病，肿瘤性疾病等，以及含有它们的药物。 本发明涉及由式（I）表示的化合物：其中每个符号如说明书中所定义，或其盐。

公开(公告)号：US20160115128A1

公开(公告)日：2016-04-28

申请号：US14898633

申请日：2014-08-08

Applicant: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Inventor： Jumpei AIDA ,  Yayoi YOSHITOMI ,  Yuko HITOMI ,  Naoyoshi NOGUCHI ,  Yasuhiro HIRATA ,  Hideki FURUKAWA ,  Akito SHIBUYA ,  Koji WATANABE ,  Yasufumi MIYAMOTO ,  Tomohiro OKAWA ,  Nobuyuki TAKAKURA ,  Seiji MIWATASHI

IPC: C07D211/34 ,  C07D413/10 ,  C07D401/14 ,  C07D405/12 ,  C07D413/14 ,  C07D401/10 ,  C07D401/12

CPC classification number: C07D211/34 ,  C07D211/22 ,  C07D213/30 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D405/14 ,  C07D409/12 ,  C07D413/10 ,  C07D413/14

Abstract: Provided is a novel aromatic ring compound having a GPR40 agonist activity and a GLP-1 secretagogue action. A compound represented by the formula: wherein each symbol is as described in the DESCRIPTION, or a salt thereof has a GPR40 agonist activity and a GLP-1 secretagogue action, is useful for the prophylaxis or treatment of cancer, obesity, diabetes, hypertension, hyperlipidemia, cardiac failure, diabetic complications, metabolic syndrome, sarcopenia and the like, and affords superior efficacy.

Abstract translation: 提供具有GPR40激动剂活性和GLP-1促分泌作用的新型芳环化合物。 由下式表示的化合物：其中每个符号如说明书所述，或其盐具有GPR40激动剂活性和GLP-1促分泌素作用，可用于预防或治疗癌症，肥胖症，糖尿病，高血压， 高脂血症，心力衰竭，糖尿病并发症，代谢综合征，肌肉减少症等，具有优异的疗效。